Relationship between metabolic syndrome and castration resistance, bone metastasis in patients with prostate cancer / 肿瘤研究与临床

ABSTRACT

Objective To investigate the association between metabolic syndrome (MS) and castrate resistance, bone metastasis in patients with prostate cancer (PCa). Methods A total of 104 patients with PCa who underwent persistent endocrine therapy in urology department of the First Hospital of Shanxi Medical University from January 2011 to June 2015 were analyzed retrospectively. They were divided into MS and non-MS group. Combined with magnetic resonance imaging (MRI), bone scanning, prostate-specific antigen (PSA) and testosterone, the patients were followed-up for 18 months. The t test was used to compare the two groups of patients reached the castration resistance period and the occurrence of bone metastases. Results There were 35 patients in MS and 69 patients in non-MS group. There was no significant difference in age, PSA, Gleason score, staging, smoking between MS group and non-MS group (all P> 0.05); there were significant differences in body mass index (BMI), fasting blood glucose, blood pressure and blood lipid between MS group and non-MS group (all P<0.05). 16 patients in MS group progressed to castration resistant prostate cancer (CRPC) and 18 patients in non-MS group progressed to CRPC, the difference was statistically significant (χ2= 4.065, P= 0.044). MS group had 11 cases of bone metastasis and non-MS group had 11 cases of bone metastasis, and the difference was statistically significant (χ2= 4.409, P= 0.036). The survival rate of patients without CRPC in MS group and non-MS group had a significant difference (χ2=7.034, P=0.021). The survival rate of patients without bone metastasis in MS group and non-MS group also had a significant difference (χ2= 6.082, P= 0.029). Conclusions MS can promote the occurrence of CRPC and bone metastasis in PCa, which is a high risk factor in the progression of the disease. PCa patients with MS should pay attention to the diagnosis and treatment of MS related diseases, which will be better for controlling PCa.